Castleview Partners’s Elevance Health ELV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.93M Buy
4,972
+269
+6% +$107K 0.85% 25
2026
Q2
$1.82M Sell
4,703
-353
-7% -$131K 0.8% 25
2026
Q1
$1.48M Sell
5,056
-350
-6% -$115K 0.76% 28
2025
Q4
$1.9M Sell
5,406
-1,237
-19% -$418K 0.94% 23
2025
Q3
$2.15M Buy
6,643
+3,085
+87% +$959K 1.17% 21
2025
Q2
$1.38M Buy
3,558
+390
+12% +$157K 0.89% 25
2025
Q1
$1.38M Buy
3,168
+842
+36% +$338K 0.93% 23
2024
Q4
$851K Buy
+2,326
New +$973K 0.46% 51
2024
Q3
– Sell
-2
Closed -$1.08K – 647
2024
Q2
$1.08K Hold
2
– – ﹤0.01% 803
2024
Q1
$1.04K Buy
+2
New +$995 ﹤0.01% 794
2023
Q2
– Sell
-35
Closed -$16.1K – 696
2023
Q1
$16.1K Buy
+35
New +$16.7K 0.01% 367
2022
Q4
– Sell
-70
Closed -$32K – 671
2022
Q3
$32K Buy
+70
New +$33.5K 0.03% 294
2022
Q2
– Sell
-70
Closed -$34K – 773
2022
Q1
$34K Buy
+70
New +$32K 0.02% 387
2021
Q2
$30K Buy
+78
New +$29.8K 0.01% 494

Other funds holding ELV

Castleview Partners's ELV Position: Q3 2026 in Review

Castleview Partners increased its Elevance Health (ELV) stake by 5.7% in Q3 2026, buying an estimated $107K and bringing the position to 4,972 shares worth $1.93M. The position accounts for 0.85% of the portfolio, ranked #25.

Castleview Partners first reported a position in ELV in Q2 2021 and has held it in 14 quarters since. The position peaked at $2.15M in Q3 2025. 236 funds tracked by Wall St. Rank hold ELV as of Q3 2026.

  • Castleview Partners held 4,972 shares of Elevance Health worth $1.93M as of Q3 2026.
  • Castleview Partners bought 269 Elevance Health shares in Q3 2026, an estimated $107K.
  • Elevance Health made up 0.85% of Castleview Partners's portfolio in Q3 2026, its #25 holding.
  • Castleview Partners first reported a position in Elevance Health in Q2 2021 and has held it in 14 quarters since.
  • Castleview Partners's Elevance Health position peaked at $2.15M in Q3 2025.
  • 236 funds tracked by Wall St. Rank held Elevance Health as of Q3 2026.

Based on Castleview Partners's 13F filing for Q3 2026, filed 9 Oct 2026.